Neha Gavin, MD
Endocrinology, Diabetes & Metabolism · Fishers, INNPI 1528226321
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $134,459 of the $149,305 with a category attached, or 90.1%. Novo Nordisk accounts for 70.5% of it on its own, with 42 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 616 payments — averaging $242.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$105K
- AstraZeneca$39K
- Amgen$1K
- Lilly USA, LLC$679
- Sanofi-aventis U.S. LLC$434
- Abbott$305
- plus $2K from 37 others
What the payments were for
- Speaking & faculty fees$134,45990%
- Travel & lodging$6,1994%
- Food & beverage$8,5266%
- Education$620%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$149,305 in reported general payments places this provider in the 95th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
See all endocrinology, diabetes & metabolism providers in Indiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 125 | $182,375 |
| MounjaroTirzepatide | 62 | $66,301 |
| Humalog Kwikpen U-200Insulin Lispro | 21 | $50,419 |
| JardianceEmpagliflozin | 51 | $42,589 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 44 | $36,815 |
| TrulicityDulaglutide | 12 | $25,806 |
| RybelsusSemaglutide | 17 | $24,144 |
| FarxigaDapagliflozin Propanediol | 29 | $20,829 |
| Humalog Kwikpen U-100Insulin Lispro | 54 | $17,118 |
| Repatha SureclickEvolocumab | 24 | $15,100 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $14,364 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 49 | $11,624 |
| Novolog FlexpenInsulin Aspart | 50 | $10,756 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $10,595 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $9,681 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $105,215 | $206,518142 claims |
| Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro | $679 | $94,881110 claims |
| Boehringer IngelheimJardiance | $126 | $42,58951 claims |
| AstraZenecaFarxiga | $39,120 | $20,82929 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $15 | $810137 claims |
| AbbVieSynthroid | $70 | $72716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
Other endocrinology, diabetes & metabolism in Fishers
- Isaiah PittmanTerre Haute$1.5M
- Ernest AsamoahIndianapolis$959K
- Erica KretchmanRichmond$609K
- Emily VeenemanSeymour$583K
- Nihad MuhrezMerrillville$271K
- Hisham AllababidiIndianapolis$195K
- Edward RicoTerre Haute$135K
- Dona GrayLafayette$92K
- Michael EconsIndianapolis$74K
- Pooja KinkhabwalaMerrillville$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.